

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 April 2020 (30.04.2020)



(10) International Publication Number
WO 2020/086506 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 7/00 (2006.01)
A61K 31/506 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2019/057316

(22) International Filing Date:

22 October 2019 (22.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/748,659	22 October 2018 (22.10.2018)	US
62/777,524	10 December 2018 (10.12.2018)	US
62/815,575	08 March 2019 (08.03.2019)	US
62/837,974	24 April 2019 (24.04.2019)	US
62/844,388	07 May 2019 (07.05.2019)	US
62/899,864	13 September 2019 (13.09.2019)	US

(71) Applicant: **RA PHARMACEUTICALS, INC.** [US/US];
87 Cambridge Park Drive, Cambridge, Massachusetts
02140 (US).

(72) Inventors: **DUDA, Petra**; 60 Pier 7, Charlestown, Mass-
achusetts 02129 (US). **FARZANEH-FAR, Ramin**; 43

Druce Street, Brookline, Massachusetts 02445 (US). **MA, Zhong**; 341 Marret Road, Unit 8, Lexington, Massachusetts 02421 (US). **ZHU, Nanqun**; 11 Blueberry Ln, Lexington, Massachusetts 02420 (US). **THACKABERRY, Evan**; 79 Skyfields Dr, Groton, Massachusetts 01450 (US). **RICARDO, Alonso**; 5 Plymouth Road, Winchester, Massachusetts 01890 (US).


(74) Agent: **SULLIVAN, Christopher P.** et al.; DT Ward PC,
142A Main Street, Groton, Massachusetts 01450 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: **NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN**

Fig. 2



(57) Abstract: The present disclosure relates methods of treating myasthenia gravis with zilucoplan (RA101495), including generalized myasthenia gravis. The present disclosure also claims devices and kits for zilucoplan administration and methods of evaluating complement inhibitor treatment efficacy.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*